Treatment with a pulsed dye laser followed immediately by intradermal botulinumtoxinA injections appears safe and improved erythema, flushing, burning and pruritus, according to a recent study.
The 21-member global ROSacea Consensus panel developed updated recommendations for rosacea, diagnosis, classification and management to support and promote transition to a phenotype approach in rosacea.
The idea that rosacea is uncommon in darker skinned individuals may be due to under-recognition. Careful clinical examination, a thorough history and biopsy in some cases are needed for accurate diagnosis and differentiating rosacea from diseases that may be more common.
ZILXI (FMX103, VYNE Therapeutics), a 1.5% topical minocycline foam, is now available for prescription for the treatment of inflammatory lesions of rosacea in adult patients.
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) filing for Sol-Gel’s Epsolay, a 5% microencapsulated benzoyl peroxide cream for the treatment of inflammatory lesions of rosacea or papulopustular rosacea.
Many patients with rosacea have features that overlap more than one subtype of the condition. A recent publication serves as a compliment to the classification guide with the intention of guiding treatment and management options based on individual patient features.
Effects of a specialized skincare regimen for sensitive and redness-prone skin were investigated in an eight-week, prospective, controlled clinical trial enrolling 60 patients with rosacea. The intervention was associated with improvements in objectively measured erythema, rosacea symptoms, and health-related quality of life.
Experts offer insights into the inflammatory pathways involved in rosacea pathogenesis, the putative anti-inflammatory mechanisms of action of treatments for rosacea, and future therapeutic needs.
A study in twins highlights exacerbating factors for patients with rosacea and the importance of the microbiome.